Payamprolizumab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Payamprolizumab, covering 2025-07-30 to 2025-07-30. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma [Phase 2]